Safety and Efficacy Study of Acthar in Subjects With ARDS

A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar® Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)

This study is being performed to evaluate the potential efficacy and safety of Acthar as a treatment for moderate-severe Acute Respiratory Distress Syndrome (ARDS). Approximately 210 subjects will be randomized to 1 of 6 possible treatment groups in a 3:2:3:2:3:2 ratio. Study medication (SM) will be administered via subcutaneous (SC) injection for 4 weeks using a blinded gradually tapering regimen, and subjects will be followed for 60 days post-randomization.

Study Overview

• Status: Withdrawn
• Conditions: Acute Respiratory Distress Syndrome
• Intervention / Treatment: Drug: Placebo; Drug: H.P. Acthar® Gel (repository corticotropin injection)

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients ≥ 18 years.

2. ARDS as defined by:

   • PaO2 /FiO2 ≤ 200 mmHg with PEEP ≥ 5cm H2O.
   • Bilateral opacities on chest radiography not explained by atelectasis, effusions, nodules, or preexisting disease.
   • Requirement for positive pressure ventilation via an endotracheal tube.
   • Respiratory failure not fully explained by cardiac failure or fluid overload. If no identifiable risk factor for ARDS is identified, left atrial hypertension must be excluded by objective measures (e.g. transthoracic echocardiogram).
   • Criteria 2a, 2b, and 2c must occur within the same 24 hr period.
3. Enrollment between 24 hours and 10 days after ARDS criteria are met.

Exclusion Criteria:

1. Subject unwilling to receive or intolerant of SC injections.
2. Subject, surrogate, or physician not committed to full supportive care. A "Do Not Resuscitate" (DNR) order alone without other limitations of care does not require study exclusion.
3. Moribund subject with death perceived to be imminent. For the purposes of this study, moribund is defined by a requirement for ≥ 2 high dose vasopressors AND acute organ failures in ≥ 3 organs for ≥ 24 hours prior to study entry.
4. Home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing prior to onset of ARDS.
5. Known contraindication to Acthar per package insert Section 4 (Appendix C): scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, or adrenal cortical hyperfunction.
6. Gastrointestinal/Hepatic: History of chronic active hepatitis, active Hepatitis B or acute or chronic Hepatitis C infection, OR moderate-severe chronic liver disease as defined by a Child-Pugh Score > 11(http://gihep.com/calculators/hepatology/child-pugh-score/), OR any evidence of hemodynamically significant active gastrointestinal (GI) bleeding.
7. Any subject with signs or symptoms concerning for an active infection that has not been treated for > 48 hours prior to randomization with either empiric broad-spectrum or pathogen-directed anti-microbial therapy.
8. Immune System: Known immune-compromised status, including but not limited to individuals who have undergone organ transplantation or who are known to be positive for the human immunodeficiency virus (HIV).
9. Burns >20% total body surface area, or any burn injury accompanied by smoke inhalational injury.
10. Major surgery within 48 hours before randomization, OR evidence of currently active bleeding postoperatively, OR plan for any major surgery during the study period.
11. Administration of any other investigational drug or participation in an interventional clinical research study for ARDS within 30 days of planned randomization or during the 60 day study duration.
12. Presence of any other clinically significant disease or disorder (including those listed in Appendix C package insert Section 5 [Warnings and Precautions]) which, in the opinion of the Investigator (by its nature or by being inadequately controlled), might put the subject at risk due to participation in the study, or may influence the results of the study or the subject's ability to complete the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; H.P. Acthar® Gel , 64 U, 0.8 mL daily	Drug: H.P. Acthar® Gel (repository corticotropin injection); Other Names: Acthar
Placebo Comparator: Group 2; Placebo, 0.8 mL, daily	Drug: Placebo
Experimental: Group 3; H.P. Acthar® Gel , 32 U, 0.4 mL, 2x daily	Drug: H.P. Acthar® Gel (repository corticotropin injection); Other Names: Acthar
Placebo Comparator: Group 4; Placebo, 0.4 mL, 2x daily	Drug: Placebo
Experimental: Group 5; H.P. Acthar® Gel , 16 U, 0.2 mL, 2x daily	Drug: H.P. Acthar® Gel (repository corticotropin injection); Other Names: Acthar
Placebo Comparator: Group 6; Placebo, 0.2 mL, 2x daily	Drug: Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of ventilator-free days (subjects alive and breathing without assistance for ≥ 48 hr) by Day 28 after randomization	60 days (28 days of treatment with a 32 day follow-up period)

Secondary Outcome Measures

Outcome Measure	Time Frame
Mortality at Day 28 and Day 60	60 days (28 days of treatment with a 32 day follow-up period)
Number of ICU-free and hospital free days for all subjects who survive to ICU and hospital discharge, respectively	60 days (28 days of treatment with a 32 day follow-up period)
Number of extra-pulmonary organ failure-free days	60 days (28 days of treatment with a 32 day follow-up period)
Change in PaO2/FiO2 ratio and oxygenation index (OI) from baseline for subjects on mechanical ventilation	60 days (28 days of treatment with a 32 day follow-up period)
Change in Systemic Organ Failure Assessment Score (SOFA) score from baseline.	60 days (28 days of treatment with a 32 day follow-up period)
Number of treatment-emergent serious adverse events	60 days (28 days of treatment with a 32 day follow-up period)
Number, severity and site of new infections developing at least 48 hr after initiation of Study Medication	60 days (28 days of treatment with a 32 day follow-up period)
Proportion of subjects who discontinue treatment because of serious safety concerns	60 days (28 days of treatment with a 32 day follow-up period)

Collaborators and Investigators

• Sponsor: Mallinckrodt

Study record dates

Study Major Dates

• Study Start (Anticipated): August 1, 2014
• Primary Completion (Anticipated): August 1, 2016
• Study Completion (Anticipated): August 1, 2016

Study Registration Dates

• First Submitted: April 8, 2014
• First Submitted That Met QC Criteria: April 14, 2014
• First Posted (Estimate): April 15, 2014

Study Record Updates

• Last Update Posted (Actual): September 27, 2017
• Last Update Submitted That Met QC Criteria: September 25, 2017
• Last Verified: September 1, 2017

More Information

Terms related to this study

• Keywords: ARDS; Acute Respiratory Distress Syndrome; ACTH; Acthar; H.P. Acthar Gel
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Respiration Disorders; Lung Diseases; Disease; Infant, Newborn, Diseases; Lung Injury; Infant, Premature, Diseases; Syndrome; Respiratory Distress Syndrome; Respiratory Distress Syndrome, Newborn; Acute Lung Injury; Physiological Effects of Drugs; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Adrenocorticotropic Hormone
• Other Study ID Numbers: QSC01-ARDS-01